These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19282778)

  • 21. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.
    ;
    AIDS; 2008 Sep; 22(14):F17-24. PubMed ID: 18753925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals.
    Marcus JL; Neugebauer RS; Leyden WA; Chao CR; Xu L; Quesenberry CP; Klein DB; Towner WJ; Horberg MA; Silverberg MJ
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):413-9. PubMed ID: 26536316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypertension Risk with Abacavir Use among HIV-Infected Individuals: A Nationwide Cohort Study.
    Kim J; Bang JH; Shin JY; Yang BR; Lee J; Park BJ
    Yonsei Med J; 2018 Dec; 59(10):1245-1252. PubMed ID: 30450860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy outcomes: data from the antiretroviral pregnancy registry.
    Vannappagari V; Koram N; Albano J; Tilson H; Gee C
    J Acquir Immune Defic Syndr; 2015 Mar; 68(3):359-64. PubMed ID: 25469525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
    Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
    Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the Data Collection on Adverse Events of Anti-HIV Drugs cohort study on abacavir prescription among treatment-naive, HIV-infected patients in Canada.
    Antoniou T; Gillis J; Loutfy MR; Cooper C; Hogg RS; Klein MB; Machouf N; Montaner JS; Rourke SB; Tsoukas C; Raboud JM;
    J Int Assoc Provid AIDS Care; 2014; 13(2):153-9. PubMed ID: 23887923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).
    Vibhagool A; Cahn P; Schechter M; Smaill F; Soto-Ramirez L; Carosi G; Montroni M; Pharo CE; Jordan JC; Thomas NE; Pearce G
    Curr Med Res Opin; 2004 Jul; 20(7):1103-14. PubMed ID: 15265255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abacavir (Ziagen(®)) use between 2003 and 2008 in France according to the electronic medical record NADIS(®).
    Dellamonica P; Katlama C; Lévy-Bachelot L; Daures JP; Finkielsztejn L
    Med Mal Infect; 2013 Dec; 43(11-12):467-74. PubMed ID: 24262915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort.
    Berenguer J; Pérez-Elías MJ; Bellón JM; Knobel H; Rivas-González P; Gatell JM; Miguélez M; Hernández-Quero J; Flores J; Soriano V; Santos I; Podzamczer D; Sala M; Camba M; Resino S;
    J Acquir Immune Defic Syndr; 2006 Feb; 41(2):154-9. PubMed ID: 16394846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
    Sosa N; Hill-Zabala C; Dejesus E; Herrera G; Florance A; Watson M; Vavro C; Shaefer M
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):422-7. PubMed ID: 16280696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
    HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations.
    Petoumenos K; Reiss P; Ryom L; Rickenbach M; Sabin CA; El-Sadr W; d'Arminio Monforte A; Phillips AN; De Wit S; Kirk O; Dabis F; Pradier C; Lundgren JD; Law MG;
    HIV Med; 2014 Nov; 15(10):595-603. PubMed ID: 24840675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
    Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
    Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
    J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.
    Wit FW; Wood R; Horban A; Beniowski M; Schmidt RE; Gray G; Lazzarin A; Lafeuillade A; Paes D; Carlier H; van Weert L; de Vries C; van Leeuwen R; Lange JM
    AIDS; 2001 Dec; 15(18):2423-9. PubMed ID: 11740193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir.
    Kowalska JD; Kirk O; Mocroft A; Høj L; Friis-Møller N; Reiss P; Weller I; Lundgren JD
    HIV Med; 2010 Mar; 11(3):200-8. PubMed ID: 19863618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.
    Law MG; Friis-Møller N; El-Sadr WM; Weber R; Reiss P; D'Arminio Monforte A; Thiébaut R; Morfeldt L; De Wit S; Pradier C; Calvo G; Kirk O; Sabin CA; Phillips AN; Lundgren JD;
    HIV Med; 2006 May; 7(4):218-30. PubMed ID: 16630034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
    Markowitz M; Hill-Zabala C; Lang J; DeJesus E; Liao Q; Lanier ER; Davis EA; Shaefer M;
    J Acquir Immune Defic Syndr; 2005 Jul; 39(3):257-64. PubMed ID: 15980684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abacavir and the potential risk of myocardial infarction.
    Cutrell A; Brothers C; Yeo J; Hernandez J; Lapierre D
    Lancet; 2008 Apr; 371(9622):1413. PubMed ID: 18387668
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.